# A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics

> **NCT05969977** · PHASE1 · UNKNOWN · sponsor: **MED-LIFE DISCOVERIES LP** · enrollment: 56 (estimated)

## Conditions studied

- Rhizomelic Chondrodysplasia Punctata

## Interventions

- **DRUG:** PPI-1011
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05969977
- **Lead sponsor:** MED-LIFE DISCOVERIES LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-29
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05969977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05969977, "A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05969977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*